Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inupadenant plus carboplatin and pemetrexed in immunotherapy-relapsed nonsquamous NSCLC
2021-005487-22Phase 2Active
- Sponsor
- iTeos Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Inupadenant + carboplatin + pemetrexed with Placebo + carboplatin + pemetrexed (2 arms). Primary endpoint: Part 1 (Dose-Finding) primary endpoint. Started May 2022; status: active.
02
Drugs
inupadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005487-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005487-22.